Electromed, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013. The supplied filing is an annual Form 10-K, not a standalone 2012 fourth-quarter filing. Fiscal 2012 is the primary comparable period.
Business Context
Electromed designs, manufactures, markets and sells SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation technology. Products are sold primarily to domestic home-care patients, as well as hospitals, institutions and international distributors. Domestic sales depend substantially on Medicare, Medicaid and private insurance reimbursement.
- International revenue represented approximately 5.2% of fiscal 2013 net revenue, compared with 2.8% in fiscal 2012.
- The company had 91 employees, including 87 full-time employees, as of June 30, 2013.
- Management changed during the year: Kathleen S. Skarvan became Chief Executive Officer in December 2012.
Financial Performance and Position
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Net revenue | $15.104 million | $19.524 million | Down 22.6% |
| Gross profit | $10.449 million | $14.145 million | Down 26.1% |
| Gross margin | 69.2% | 72.4% | Down 3.2 percentage points |
| Operating income (loss) | $(1.827) million | $0.606 million | Declined $2.434 million |
| Net income (loss) | $(1.329) million | $0.187 million | Declined $1.516 million |
| Basic and diluted EPS | $(0.16) | $0.02 | Declined $0.18 |
| Cash flow from operations | $1.877 million | $(1.172) million | Improved $3.049 million |
Home-care revenue declined 28.2% to $12.892 million. International revenue increased 43.0% to $782,000, and government/institutional revenue increased 40.5% to $1.430 million. SG&A expense declined 7.5% to $11.673 million, while research and development expense declined to $603,000 from $921,000.
The fiscal 2013 income tax benefit was $615,000, compared with tax expense of $251,000 in fiscal 2012. The reported tax benefit materially reduced the net loss but does not represent operating cash generation.
Cash Flow, Debt and Liquidity
- Cash and cash equivalents were $504,000 at June 30, 2013, down from $1.702 million.
- Accounts receivable declined to $9.014 million from $10.851 million, and inventories declined to $1.380 million from $2.392 million.
- Capital expenditures were $1.017 million, compared with $792,000 in fiscal 2012.
- Financing cash outflows were $2.022 million, including $1.768 million of revolving-line repayments and $254,000 of long-term debt repayments.
- Total debt was approximately $1.390 million, consisting primarily of a $1.365 million mortgage/term loan and $25,000 of capital lease obligations.
- The company had no revolving-line borrowings and reported $2.250 million of unused availability under its credit facility at June 30, 2013.
- Management stated that approximately $10 million of working capital and available borrowings were expected to provide adequate liquidity for the following year.
Material Changes Versus Prior Period
- Revenue deterioration was concentrated in domestic home-care sales, primarily because of lower reimbursement pricing, longer payer approval procedures and the decentralization of contracting by a major payer.
- Sales-force turnover increased the proportion of less-tenured Clinical Area Managers and negatively affected certain territories.
- Lower revenue reduced manufacturing-cost leverage and lowered gross margin.
- Legal and professional fees increased by approximately $306,000, primarily due to shareholder-proposal litigation and information-technology consulting.
- Advertising and marketing expense decreased by approximately $565,000 after marketing activities were brought in-house and spending was redirected toward lower-cost initiatives.
- The company incurred a $50,000 increase in SG&A related to the U.S. medical-device excise tax effective January 1, 2013.
- Research and development spending decreased 34.5%, although management continued to target spending of up to 5% of net revenue on R&D.
Outlook, Risks and Unusual Items
Management’s recovery plan focused on cost control, rebuilding and realigning the domestic sales force, improving reimbursement processes, refreshing the SmartVest brand, expanding international distribution and developing additional products and services. The filing does not provide a specific fiscal 2014 revenue or earnings forecast.
- The credit facility expired on December 31, 2013 unless renewed. Management expected renewal or alternative financing but stated that financing on favorable terms could not be guaranteed.
- The company violated certain credit-facility covenants during fiscal 2013, and the bank waived the defaults. A July 8, 2013 amendment removed the covenants as of June 30, 2013 and adjusted future requirements.
- Future covenant violations, failure to renew the credit line or accelerated debt maturity could materially affect liquidity and operations. Debt is secured by substantially all tangible and intangible assets.
- Reimbursement reductions, payer policy changes, delayed approvals and denial of coverage remain major operating risks.
- The company recorded approximately $2.290 million of estimated unrecognized installment-sale revenue at June 30, 2013; installment revenue recognized during fiscal 2013 was $1.029 million.
- Shareholder and former executive litigation was settled after year-end. The former CEO settlement required a $150,000 payment; the company expected insurance to cover a majority of litigation-related fees but could not guarantee the amount of coverage.
- The company changed certain warranty terms for sales after June 30, 2013, generally moving from multiple regional warranty periods to a lifetime U.S. patient warranty and three-year warranties for other sales.
- Competition, FDA and foreign regulatory compliance, intellectual-property protection, healthcare fraud and privacy laws, and the 2.3% medical-device excise tax remain material risks.
Investor Verification Points
- Verify the subsequent renewal, refinancing or repayment of the credit facility after its December 31, 2013 expiration date.
- Review fiscal 2014 trends in domestic home-care revenue, reimbursement rates, payer contracting and accounts-receivable collections.
- Assess whether gross margin recovered toward management’s stated historical level above 70%.
- Confirm the cash impact and insurance reimbursement associated with the shareholder and former executive litigation settlements.
- Reconcile reported operating cash flow with the net loss, particularly the effects of accounts receivable, inventory reductions and installment-sale accounting.
- Monitor whether international and institutional growth can offset continued weakness in domestic home-care sales.
- Review the company’s ability to remain compliant with amended credit covenants while funding sales, R&D and capital expenditures.